Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by $2.15, Revenues Rise 3400%; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
March 4, 2021 4:05 PM ESTFourth Quarter 2020 Results:
Record Revenue of $295.0 million, growing more than 3,400% year-over-yearRecord Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019Gross Margin improved over 8 percentage points sequentially and approximately 26 percentage points year-over-year; cost per test improved approximately 36% sequentiallyNon-COVID Revenue grew 43% year-over-yearRecord GAAP income of $166.3 million, or $6.16 per shareRecord Non-GAAP income of $167.5 million, or $6.20 per shareRecord Adjusted EBITDA of $230.1 million2021 Outlook:
... More